La Jolla Light’s Corey Levitan explores shared insights at Sanford Burnham Prebys Medical Discovery Institute where a dynamic group came together to explore new approaches to a baffling disease of rheumatoid arthritis (RA) at the Insights Symposium.
When it comes to precision medicine we are just at the era of the Model T reports Carl Ware. The current front line war on autoimmune diseases are NK-KB inhibitors, which are described as significantly effective on a subset of patients. But nearly 70% of patients don’t respond well and it is not known why.
Angela Durazo, a triathlete, is one of those unresponsive patients at the height of her career. However, she was forced to retire because RA knocked her out of the game. She is quoted “I went from being a star athlete to not being able to open a water bottle.” She couldn’t ride a bike anymore. She couldn’t run. It was devasting. She sank to depths of depression, alcoholism, and generally lost. Now with radical new RA treatment options and auto racing she has a new lease on life! Treatments include seven-week cycles of the androgen steroid hormone DHEA, twice-weekly glutathione injections and Pentadecapeptide BPC 157, which she describes as “an oxidizing molecule that works on a telomere level to reconstruct the cell.”
Sanford Burnham Prebys Medical Discovery Institute
Sanford Burnham Prebys Medical Discovery Institute (SBP) is a non-profit medical research institute located in La Jolla, California. There are more than 500 scientists at SBP blending fundamental research with drug discovery to address unmet clinical needs in the areas of cancer, neuroscience, immunity, and childhood diseases.
Research at SBP is supported by funding from the National Institutes of Health, National Cancer Institute, and Juvenile Diabetes Research Foundation among others and partnerships with pharmaceutical companies such as Johnson & Johnson Pharmaceutical Research and Development. In 2008, SBP was awarded a $97.9 million grant by NIH to establish a high-throughput screening center.